HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up-Reference-Cited by-同舟云学术

HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up

Published:2016-07 Issue: Volume:62 Page:62-75
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Jackisch Christian,Hegg Roberto,Stroyakovskiy Daniil,Ahn Jin-Seok,Melichar Bohuslav,Chen Shin-Cheh,Kim Sung-Bae,Lichinitser Mikhail,Starosławska Elżbieta,Kunz Georg,Falcon Silvia,Chen Shou-Tung,Crepelle-Fléchais Aulde,Heinzmann Dominik,Shing Mona,Pivot Xavier

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference26 articles.

1. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer;DeCock;Cancer Med,2016

2. Subcutaneous trastuzumab (Herceptin®): a UK time and motion study in comparison with intravenous formulation for the treatment of patients with HER2-positive early breast cancer;Burcombe;Adv Breast Cancer Res,2013

3. Subcutaneous trastuzumab for HER2-positive breast cancer – evidence and practical experience in 7 German centers;Jackisch;Geburtshilfe Frauenheilkd,2015

4. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study;Pivot;Lancet Oncol,2013

5. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study;Pivot;Ann Oncol,2014

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial);JCO Oncology Practice;2024-07-19

2. Tailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations;Cancer;2024-07-10

3. QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial;British Journal of Cancer;2024-06-21

4. Subcutaneous versus intravenous administration of Trastuzumab: a minimization cost analysis with real world data from a reference cancer centre in Peru;ecancermedicalscience;2024-05-31

5. “Heterogeneity of treatment effect on patients’ long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer.”;The Breast;2024-02